Related Experiment Videos
Arginine vasopressin release from human platelets after irreversible aggregation
G Anfossi1, E Mularoni, M Trovati
1Clinica Medica Generale III, University of Turin, Ospedale S. Luigi Gonzaga, Orbassano (TO), Italy.
Clinical Science (London, England : 1979)
|January 1, 1990
Summary
Arginine vasopressin (AVP) is released from human platelets during aggregation induced by various agents. Physiologically relevant AVP levels enhance platelet sensitivity and potentiate responses to other agonists.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Platelets play a crucial role in hemostasis and thrombosis.
- Arginine vasopressin (AVP) is a hormone known for its vasoconstrictive properties.
- The role of AVP within platelets is not fully understood.
Purpose of the Study:
- To investigate the release of arginine vasopressin (AVP) from human platelets.
- To determine if AVP is released following platelet aggregation induced by various agents.
- To explore the functional significance of platelet-derived AVP.
Main Methods:
- Human platelet-rich plasma was used for in vitro studies.
- Platelet aggregation was induced using adenosine 5'-pyrophosphate, collagen, sodium arachidonate, thrombin, and adrenaline.
- Arginine vasopressin levels in the supernatant were measured using radioimmunoassay.
Main Results:
- Significantly higher AVP levels were detected in the supernatant of stimulated platelets compared to unstimulated controls.
- Collagen and adrenaline induced the highest AVP release.
- Physiologically relevant AVP concentrations enhanced platelet sensitivity to adenosine 5'-pyrophosphate and collagen.
- AVP potentiated catecholamine effects on platelet response to sodium arachidonate.
Conclusions:
- Intraplatelet arginine vasopressin is released during platelet aggregation.
- Local AVP release from platelets may occur following aggregation in vivo.
- Platelet-derived AVP may contribute to platelet activation and aggregation processes.